Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
Chuikyo OKs Listing of Harvoni, Peak Sales Put at 119 Billion Yen in 2nd Year
The Central Social Insurance Medical Council (Chuikyo) on August 26 approved the NHI price listing of Gilead Sciences K.K.’s chronic hepatitis C drug Harvoni (ledipasvir + sofosbuvir), which is expected to rack up 119 billion yen in the second year…
To read the full story
Related Article
- Harvoni, Yervoy, Other New Drugs Hit Japan Market
September 1, 2015
- Panel OKs Medical Subsidy for Harvoni, Monthly Copay Up to 20,000 Yen
August 28, 2015
- Commentary: Spiking Drug Prices Behind Harvoni Pricing Spat at Chuikyo
August 28, 2015
- Chuikyo Reps Trade Barbs over Pricing of Harvoni, Listing OK'ed by a Whisker
August 27, 2015
REGULATORY
- Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
- 2024 Reform Spurred New Development Activity, 20 Projects Entered Clinic: Industry Poll
December 11, 2025
- Regenerative Medicine Group Accepts Deferred Debate on Market Expansion Re-Pricing
December 11, 2025
- Wholesalers Urge Price Hikes on Sub-20-Yen Drugs as Negative Margins Mount
December 11, 2025
- Two Bayer/AskBio Gene Therapies Bag Sakigake Designation
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…